Joel Van Heukelom

Dr. Joel Van Heukelom


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2023 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
SCSavannah Collett
Savannah Collett
AMAmanda Massmann
Amanda Massmann
NPNatasha J. Petry
Natasha J. Petry
JHJoel Van Heukelom
Joel Van Heukelom
ASApril Schultz
April Schultz
JBJordan Baye
Jordan Baye
Metoprolol is a medication commonly utilized in select patients to achieve a reduction in heart rate, systolic blood pressure, or other indications. A majority of metoprolol metabolism occurs via CYP2D6. Decreased expression of the CYP2D6 enzyme increases the concentration of metoprolol. Current pharmacogenomics guidelines by the Dutch Pharmacogenomics Working Group recommend slower titrations and dose decreases to minimize adverse effects from poor metabolizers or normal metabolizers taking concomitant medications that are strong inhibitors of CYP2D6 (phenoconverters). This study aimed to evaluate adverse effects such as bradycardia, hypotension, and syncope in patients who are expected to have absent CYP2D6 enzyme activity due to drug–drug or drug–gene interactions. The secondary aims of this study were to evaluate heart rate measurements for the included participants. Retrospective data were collected for individuals with CYP2D6 genotyping results obtained for clinical purposes. Three categories (CYP2D6 normal metabolizers, poor metabolizers, and phenoconverters) were assigned. A total of 325 participants were included. There was no statistically significant difference found in the primary composite outcome between the three metabolizer groups (p = 0.054). However, a statistically significant difference was identified in the incidences of bradycardia between the poor metabolizers and the normal metabolizers or phenoconverters (p < 0.0001). The average heart rates were 2.8 beats per minute (bpm) and 2.6 bpm lower for the poor metabolizer and phenoconverter groups, respectively, compared to the normal metabolizers (p < 0.0001 for both comparisons). This study further supports the role of genetic testing in precision medicine to help individualize patient care as CYP2D6 poor metabolizers taking metoprolol were found to have an increase in bradycardia. Additional research is needed to clarify the dose relationship in this drug–gene interaction.

17 July 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
CPCharlene L Preys
Charlene L Preys
CZCarrie L Blout Zawatsky
Carrie L Blout Zawatsky
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
RGRobert C Green
Robert C Green
KCKurt Christensen
Kurt Christensen
Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx testing and its perceived util...

14 November 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JHJoel Van Heukelom
Joel Van Heukelom
JMJennifer Morgan
Jennifer Morgan
AMAmanda Massmann
Amanda Massmann
KJKristen Jacobsen
Kristen Jacobsen
NPNatasha J. Petry
Natasha J. Petry
ASApril Schultz
April Schultz
Introduction: Pharmacogenomics (PGx) aims to maximize drug benefits while minimizing risk of toxicity. Although PGx has proven beneficial in many settings, clinical uptake lags. Lack of clinician confidence and limited availability of PGx testing can deter patients from completing PGx testing. A few novel PGx clinic models have been described as a way to incorporate PGx testing into the standard of care.Background: A PGx clinic was implemented to fill an identified gap in provider availability, confidence, and utilization of PGx across our health system. Through a joint pharmacist and Advanced Practice Provider (APP) collaborative clinic, patients received counseling and PGx medication recommendations both before and after PGx testing. The clinic serves patients both in-person and virtually across four states in the upper Midwest.Results: The majority of patients seen in the PGx clinic during the early months were clinician referred (77%, n = 102) with the remainder being self-referred. Patients were, on average, taking two medications with Clinical Pharmacogenetics Implementation Consortium guidelines. Visits were split almost equally between in-person and virtual visits.Conclusion: Herein, we describe the successful implementation of an interdisciplinary PGx clinic to further enhance our PGx program. Throughout the implementation of the PGx clinic we have learned valuable lessons that may be of interest to other implementors. Clinicians were actively engaged in clinic referrals and early adoption of telemedicine was key to the clinic’s early successes.

26 April 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
JHJoel Van Heukelom
Joel Van Heukelom
KJKristen Jacobsen
Kristen Jacobsen
NPNatasha J Petry
Natasha J Petry
ASApril Schultz
April Schultz
JBJordan Baye
Jordan Baye
AMAmanda Massmann
Amanda Massmann
Background: Returning pharmacogenomic (PGx) results to patients is complex and challenging. Patients prefer provider education; however, a gap in provider comfort in PGx results has been documented...

26 May 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
RGRobert C Green
Robert C Green
CHCatherine Hajek
Catherine Hajek
MHMadison R Hickingbotham
Madison R Hickingbotham
ASApril Schultz
April Schultz
Background: SLCO1B1 variants are known to be a strong predictor of statin-associated muscle symptoms (SAMS) risk with simvastatin. Methods: The authors conducted a retrospective chart review on 20,...

12 June 2024 in Pharmacogenomics
Verified
Journal Article
Closed access
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
MWMax Weaver
Max Weaver
ASApril Schultz
April Schultz
DFDebbie M Figueroa
Debbie M Figueroa
KCKurt Christensen
Kurt Christensen
Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001).Conclusion: CDS for CYP2C19-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.